StreetInsider.com News Articles

WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

Thu, 24 Sep 2026 08:47:00 -0400

WUXI, China, Sept. 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its drug substance (DS) and drug product (DP) manufacturing facilities at the Wuxi Mashan site successfully passed a two-week GMP inspection conducted by the U.S. Food and Drug Administration (FDA). The successful inspection further strengthens the Company's capabilities to ensure the reliable supply of its partners' commercial products to the U.S. market.

WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

Thu, 24 Sep 2026 08:47:00 -0400

WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

Wed, 16 Sep 2026 04:57:00 -0400

SHANGHAI, Sept. 16, 2026 /PRNewswire/ -- Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China as one of the representative companies in ESG data governance.

The 2026 Forbes China ESG 50 list

WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

Wed, 16 Sep 2026 04:57:00 -0400

The 2026 Forbes China ESG 50 list

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$60 at JPMorgan

Fri, 28 Aug 2026 09:18:01 -0400

JPMorgan analyst Yang Huang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$60.00 (from HK$47.00) while maintaining a Overweight rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$60 at JPMorgan

Fri, 28 Aug 2026 09:18:01 -0400

JPMorgan analyst Yang Huang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$60.00 (from HK$47.00) while maintaining a Overweight rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$60 at JPMorgan

Fri, 28 Aug 2026 09:18:01 -0400

JPMorgan analyst Yang Huang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$60.00 (from HK$47.00) while maintaining a Overweight rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$60 at JPMorgan

Fri, 28 Aug 2026 09:18:01 -0400

JPMorgan analyst Yang Huang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$60.00 (from HK$47.00) while maintaining a Overweight rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$62 at Citi

Fri, 28 Aug 2026 03:01:07 -0400

Citi analyst John Yung raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$62.00 (from HK$42.00) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$62 at Citi

Fri, 28 Aug 2026 03:01:07 -0400

Citi analyst John Yung raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$62.00 (from HK$42.00) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$62 at Citi

Fri, 28 Aug 2026 03:01:07 -0400

Citi analyst John Yung raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$62.00 (from HK$42.00) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$62 at Citi

Fri, 28 Aug 2026 03:01:07 -0400

Citi analyst John Yung raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$62.00 (from HK$42.00) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$61 at Macquarie

Thu, 27 Aug 2026 08:11:38 -0400

Macquarie analyst Tony Ren raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$61.00 (from HK$47.00) while maintaining a Outperform rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$61 at Macquarie

Thu, 27 Aug 2026 08:11:38 -0400

Macquarie analyst Tony Ren raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$61.00 (from HK$47.00) while maintaining a Outperform rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$61 at Macquarie

Thu, 27 Aug 2026 08:11:38 -0400

Macquarie analyst Tony Ren raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$61.00 (from HK$47.00) while maintaining a Outperform rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$61 at Macquarie

Thu, 27 Aug 2026 08:11:38 -0400

Macquarie analyst Tony Ren raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$61.00 (from HK$47.00) while maintaining a Outperform rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$60.22 at Nomura/Instinet

Wed, 26 Aug 2026 06:50:15 -0400

Nomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$60.22 (from HK$51.38) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$60.22 at Nomura/Instinet

Wed, 26 Aug 2026 06:50:15 -0400

Nomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$60.22 (from HK$51.38) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$60.22 at Nomura/Instinet

Wed, 26 Aug 2026 06:50:15 -0400

Nomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$60.22 (from HK$51.38) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$60.22 at Nomura/Instinet

Wed, 26 Aug 2026 06:50:15 -0400

Nomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$60.22 (from HK$51.38) while maintaining a Buy rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$49 at Goldman Sachs

Wed, 26 Aug 2026 06:39:49 -0400

Goldman Sachs analyst Ziyi Chen raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$49.00 (from HK$43.10) while maintaining a Neutral rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$49 at Goldman Sachs

Wed, 26 Aug 2026 06:39:49 -0400

Goldman Sachs analyst Ziyi Chen raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$49.00 (from HK$43.10) while maintaining a Neutral rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$49 at Goldman Sachs

Wed, 26 Aug 2026 06:39:49 -0400

Goldman Sachs analyst Ziyi Chen raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$49.00 (from HK$43.10) while maintaining a Neutral rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$49 at Goldman Sachs

Wed, 26 Aug 2026 06:39:49 -0400

Goldman Sachs analyst Ziyi Chen raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$49.00 (from HK$43.10) while maintaining a Neutral rating.

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$57 at Morgan Stanley

Wed, 26 Aug 2026 01:28:13 -0400

Morgan Stanley analyst Laurence Tam raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$57.00 (from HK$50.00) while maintaining a Overweight rating.